On June 28, 2024, Shengnuo Medicine-B (02257) announced that Ms. Huang Mengying, an independent non-executive director, was appointed as a member of the audit committee; Dr. Chang Haibo, an independent non-executive director and a member of the nomination committee, was appointed as the chairman of the nomination committee; and Ms. Sheng Muxian, an independent non-executive director, was appointed as a member of the nomination committee.
圣诺医药-B(02257)：于常海获委任为提名委员会主席
Shenguo Pharmaceuticals-B (02257): Yu Changhai was appointed as the chairman of the nomination committee.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.